---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-047360"
form_type: "8-K"
ticker: "ATYR"
cik: "0001339970"
company_name: "aTYR PHARMA INC"
filed_at: "2023-09-11T23:59:59+00:00"
generated_at: "2026-06-10T21:37:17.180853+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "medium"
source: SEC EDGAR
---

# aTyr Pharma reports positive Phase 1b/2a post-hoc data for efzofitimod in sarcoidosis

## Summary
- Therapeutic doses (3.0 & 5.0 mg/kg) reduced steroid relapse rate to 7.7% vs 54.4% (p=0.017).
- FVC rate of change significantly improved for therapeutic vs placebo/subtherapeutic group (p=0.035).
- 52.9% of therapeutic group achieved ≥12 KSQ-L improvement (3x MCID) vs 15.0% (p=0.032).
- 64.7% of therapeutic group met composite responder endpoint vs 20.0% (p=0.008).

## SEC filing metadata
- accession: 0000950170-23-047360
- form_type: 8-K
- ticker: ATYR
- cik: 0001339970
- company_name: aTYR PHARMA INC
- filed_at: 2023-09-11T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: medium
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339970/000095017023047360/0000950170-23-047360-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339970/000095017023047360/life-20230910.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-047360
- JSON: https://secwatch.observer/filing/0000950170-23-047360.json
- Plain text: https://secwatch.observer/filing/0000950170-23-047360.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.